What is Angiodroid?
Headquartered in Italy, Angiodroid operates as a medical device manufacturer, focusing on innovative solutions within the healthcare technology landscape. The company's commitment to advancing medical technology positions it as a key contributor to the evolving medtech sector. Its strategic positioning is further solidified by the substantial capital injections it has received, enabling it to pursue ambitious research, development, and commercialization strategies.
How much funding has Angiodroid raised?
Angiodroid has raised a total of $9.2M across 2 funding rounds:
Unspecified
$1.6M
Series A
$7.6M
Unspecified (2015): $1.6M with participation from Innogest and ZernikeMeta Ventures
Series A (2023): $7.6M led by CDP Venture Capital, ALIAD, and 8a+ Investment SGR
Key Investors in Angiodroid
CDP Venture Capital
CDP Venture Capital is an investment firm that likely focuses on supporting Italian startups and innovative companies, particularly those with high growth potential in strategic sectors like technology and healthcare.
Innogest
Innogest Capital is an investment firm that focuses on partnering with entrepreneurial visionaries to support companies that create significant impact. They specialize in sectors such as technology and healthcare.
ZernikeMeta Ventures
ZernikeMeta Ventures is an investment firm that likely supports early-stage and growth-stage companies, with a potential focus on technology and innovation-driven businesses.
What's next for Angiodroid?
With the recent influx of major strategic investment and a robust history of enterprise-level funding, Angiodroid is poised for significant expansion. The company is likely to leverage this capital to accelerate product innovation, scale its manufacturing capabilities, and broaden its market penetration. Future developments may include strategic partnerships, further technological advancements, and an increased global presence, solidifying its role as a leader in the medtech field.
See full Angiodroid company page
